Skip to main content

Advertisement

Fig. 3 | BMC Infectious Diseases

Fig. 3

From: Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations

Fig. 3

Impact of BPaMZ regimen use and barrier to resistance on potentially infectious person-time. Total time with drug-resistant TB (left column) includes the time prior to the first treatment within the model, while the right column shows time with active drug-resistant TB after an individual has begun treatment at least once within the model – that is, time and potential transmission that better treatment might have prevented. For comparison, in the Current Care scenario, total time with TB (with or without drug resistance) was 8900 person-months overall and 1400 person-months after a treatment attempt, per 100 TB cases. Acquired resistance risk parameters increase risks of moxifloxacin, bedaquiline, and pretomanid resistance during BPaMZ, and also of isoniazid resistance during HRZE

Back to article page